Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Sodium sulphomethyl derivatives of polymyxins. Colistin: revival of an old polymyxin antibiotic. 2006 50(6):1953–8.ĭijkmans AC, Wilms EB, Kamerling IM, Birkhoff W, Ortiz-Zacarias NV, van Nieuwkoop C, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. In vitro activity of polymyxins in combination with beta-lactams against clinical strains of Pseudomonas aeruginosa. Mitsugui CS, Tognim MC, Cardoso CL, Carrara-Marroni FE, Botelho GL. Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Colistin and polymyxin B susceptibility testing for crbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with broth microdilution. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Hu FP, Guo Y, Yang Y, Zheng YG, Wu S, Jiang XF, et al. Content source: Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Neutrophil gelatinase-associated lipocalin PK: Ratio of area under curve of free colistin over minimum inhibitory concentration f mįraction of CMS converted into colistin in blood MIC: Steady-state 24-h area under the concentration-time curve BMI:Ĭysteine dehydrogenase inhibitor C fAUC/MIC: The difference in component content in the two CMS formulas had a significant ( P < 0.001) impact on the systemic exposure of colistin in human, thus, warranted essential considerations in clinical applications.Īrea under the concentration–time curve from time 0 to 12 h after drug administration AUC 0–24Īrea under the concentration–time curve from time 0 to 24 h after drug administration AUC 0-infĪrea under the concentration–time curve from time zero to infinity after drug administration AUC ss,24 μg/mL for CTTQ and Parkedale, respectively.The systemic exposure (AUC 0-inf) of CMS were 59.49 ± 5.90 h The PK parameters after a single intravenous infusion of CMS at 2.5 mg/kg were calculated and the steady-state plasma colistin concentrations (C ss,avg) following multiple dosing, once every 12 h for 7 days, were simulated with the non-compartment model. Both CMS formulas met the requirements of European Pharmacopoeia 9.2 with 12.1% difference in the two major active components (CMS A and CMS B). Two CMS formulas (CTTQ and Parkedale) were investigated in a single dose, randomized, open-label, crossover study conducted in 18 healthy Chinese subjects. To evaluate the effects of component contents in different colistin methanesulfonate (CMS) formulas on their clinical pharmacokinetics of the prodrug CMS and the formed colistin.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |